Skip to content
GLP-1 Desk
Menu
Dispatch #2Editorial

Vaylen

The strongest all-rounder among the newer entrants — low pricing, brand access, oral routes, and all 50 states on one account.

Visit VaylenEditorial — no commercial relationship.
Semaglutide
$179/mo
Tirzepatide
$239/mo
Coverage
All 50 states
Brand-name
Yes

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency88/100
State access96/100
Molecule range96/100
Onboarding speed86/100
Support responsiveness84/100
Licensing & trust90/100

What the Desk likes

  • Brand-name and compounded access on both molecules
  • Oral and injectable routes available
  • Nationwide 50-state coverage at below-market pricing

Where points come off

  • Newer operator with a shorter track record
  • Support depth still unproven at scale

The Desk's briefing — A−

Best for: People who want maximum optionality — brand or compounded, oral or injectable — without giving up nationwide reach.

Vaylen ranks #2 of 25 providers scored — see #1, CoreAge Rx on the board.

Related dispatches

Pricing and verification reflect Vaylen's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Vaylen's site. Not medical advice; see our disclosure.

← Back to The Desk